Cancer diagnostics company Foundation Medicine has signed deals with four pharmaceutical companies this year, allowing those companies to use its clinical cancer genomic test. In early 2011, Foundation inked deals with Novartis, Celgene, and an undisclosed company, and it recently signed a similar deal with Johnson & Johnson Pharmaceutical Research and Development. Foundation Medicine's test uses next-generation sequencing to analyze small formalin-fixed, paraffin-embedded tumor samples, and checks for mutations in more than 200 cancer-related genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.